|
The Community IntraVenous Antibiotic Study (CIVAS): a mixed-methods evaluation of patient preferences for and cost-effectiveness of different service models for delivering outpatient parenteral antimicrobial therapy |
Minton J, Czoski Murray C, Meads D, Hess S, Vargas-Palacios A, Mitchell E, Wright J, Hulme C, Raynor D K, Gregson A, Stanley P, McLintock K, Vincent R & Twiddy M |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Minton J, Czoski Murray C, Meads D, Hess S, Vargas-Palacios A, Mitchell E, Wright J, Hulme C, Raynor D K, Gregson A, Stanley P, McLintock K, Vincent R & Twiddy M. The Community IntraVenous Antibiotic Study (CIVAS): a mixed-methods evaluation of patient preferences for and cost-effectiveness of different service models for delivering outpatient parenteral antimicrobial therapy. Health Services and Delivery Research 2017; 5(6) Authors' objectives Outpatient parenteral antimicrobial therapy (OPAT) is widely used in most developed countries, providing considerable opportunities for improved cost savings. However, it is implemented only partially in the UK, using a variety of service models.
The aims of this research were to (1) establish the extent of OPAT service models in England and identify their development; (2) evaluate patients' preferences for different OPAT service delivery models; (3) assess the cost-effectiveness of different OPAT service delivery models; and (4) convene a consensus panel to consider our evidence and make recommendations. Authors' conclusions The quantitative preference analysis and economic modelling favoured a SN model, although there are differences between sociodemographic groups. SA provides cost savings for long-term treatment but is not appropriate for all. Indexing Status Subject indexing assigned by CRD MeSH Administration, Intravenous; Anti-Bacterial Agents; Anti-Infective Agents; Computer Systems; Cost-Benefit Analysis; Humans; Infusions, Intravenous; Outpatients; Patient Preference Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence HS&DR Programme, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, University of Southampton, Alpha House, Enterprise Road, Southampton, SO16 7NS, UK Tel: +44 23 8059 4304
Email: hsdrinfo@southampton.ac.uk AccessionNumber 32017000145 Date abstract record published 24/02/2017 |
|
|
|